Be on our

Show

To be a part of BuxMont Live Sign up Now!
icon-1
 

Promote your

Event

Tell Us and We’ll Read it On Air.

icon-3

Bring the

Music

Share your music on BuxMont Live radio

icon-4

Genentech's Ocrevus Offers Stiff Competition to the New High-Efficacy Oral Therapies, Novartis' Mayzent and EMD Serono's Mavenclad, While Biogen's Vumerity Begins to Chip Away at the Company's Own Tecfidera

Written by John Ralston on . Posted in Uncategorized

Genentech's Ocrevus Offers Stiff Competition to the New High-Efficacy Oral Therapies, Novartis' Mayzent and EMD Serono's Mavenclad, While Biogen's Vumerity Begins to Chip Away at the Company's Own TecfideraEXTON, Pa., March 10, 2020 /PRNewswire/ — In the last year, the US multiple sclerosis (MS) market saw the introduction of three new disease-modifying therapies (DMTs) for the treatment of relapsing forms of MS (RMS). Fielded between January 21 and…

Tags: